MX2023003273A - Ligandos de nlrx1. - Google Patents
Ligandos de nlrx1.Info
- Publication number
- MX2023003273A MX2023003273A MX2023003273A MX2023003273A MX2023003273A MX 2023003273 A MX2023003273 A MX 2023003273A MX 2023003273 A MX2023003273 A MX 2023003273A MX 2023003273 A MX2023003273 A MX 2023003273A MX 2023003273 A MX2023003273 A MX 2023003273A
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- disease
- chronic
- inflammatory
- compounds
- Prior art date
Links
- 101150046293 Nlrx1 gene Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 101001109452 Homo sapiens NLR family member X1 Proteins 0.000 abstract 2
- 102100022697 NLR family member X1 Human genes 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002757 inflammatory effect Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000003959 neuroinflammation Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención proporciona compuestos que se dirigen al dominio de oligomerización de unión a nucleótidos, vía X1 (NLRX1) que contiene repeticiones ricas en leucina. Los compuestos se pueden usar para tratar afecciones tales como enfermedades autoinmunes, enfermedades alérgicas, enfermedades crónicas y/o inflamatorias del sistema nervioso central, enfermedades respiratorias crónicas y/o inflamatorias, cáncer y enfermedades infecciosas. Las condiciones ejemplares incluyen esclerosis múltiple, asma, enfermedad de Alzheimer, enfermedad de Parkinson, neuroinflamación resultante de, por ejemplo, accidente cerebrovascular, lesión cerebral traumática o lesión de la médula espinal, enfermedad pulmonar obstructiva crónica, fibrosis pulmonar idiopática y enfermedad inflamatoria intestinal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063081016P | 2020-09-21 | 2020-09-21 | |
| PCT/US2021/051068 WO2022061224A1 (en) | 2020-09-21 | 2021-09-20 | Nlrx1 ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003273A true MX2023003273A (es) | 2023-04-26 |
Family
ID=80739968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003273A MX2023003273A (es) | 2020-09-21 | 2021-09-20 | Ligandos de nlrx1. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11548885B2 (es) |
| EP (1) | EP4196475A1 (es) |
| JP (1) | JP2023542921A (es) |
| KR (1) | KR20230074174A (es) |
| CN (1) | CN116368133A (es) |
| AR (1) | AR123560A1 (es) |
| AU (1) | AU2021342568A1 (es) |
| BR (1) | BR112023005189A2 (es) |
| CA (1) | CA3192644A1 (es) |
| CL (1) | CL2023000803A1 (es) |
| IL (1) | IL301346A (es) |
| MX (1) | MX2023003273A (es) |
| WO (1) | WO2022061224A1 (es) |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2212814T3 (es) | 1996-10-31 | 2004-08-01 | Harbor Branch Oceanographic Institution, Inc. | Uso de compuestos y composiciones antiinflamatorias neurogenicas. |
| JP2002512628A (ja) | 1997-06-13 | 2002-04-23 | スージェン・インコーポレーテッド | タンパク質チロシン酵素関連の細胞信号伝達を調節するための新規ヘテロアリール化合物 |
| JPH1180110A (ja) | 1997-09-02 | 1999-03-26 | Fuji Photo Film Co Ltd | ジアゾニウム塩および感熱記録材料 |
| JP4244251B2 (ja) | 1999-02-22 | 2009-03-25 | 富士フイルム株式会社 | ジアゾ化合物および感熱記録材料 |
| US6197488B1 (en) | 1999-07-21 | 2001-03-06 | Eastman Kodak Company | Color photographic element containing a coupler releasing derivative with at least three heteroatoms with specific hydrophobicity |
| AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| IL156595A0 (en) | 2001-01-16 | 2004-01-04 | Astrazeneca Ab | Therapeutic heterocyclic compounds |
| AU2002305926A1 (en) | 2001-02-05 | 2002-10-08 | Exegenics Inc. | Cysteine protease inhibitors |
| PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
| DK3042894T1 (da) | 2001-08-10 | 2016-11-07 | Shionogi & Co | Antiviralt middel |
| CA2465491A1 (en) | 2001-11-07 | 2003-05-15 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| CA2443023A1 (en) | 2002-02-01 | 2003-08-07 | King Pharmaceuticals Research And Development, Inc. | 8-heteroaryl xanthine adenosine a2b receptor antagonists |
| DE602004022819D1 (de) | 2003-06-06 | 2009-10-08 | Vertex Pharma | Von atp-bindende kassette transportern |
| JP5147401B2 (ja) | 2005-09-06 | 2013-02-20 | 塩野義製薬株式会社 | Ｐｇｄ２受容体アンタゴニスト活性を有するインドールカルボン酸誘導体 |
| WO2007057782A2 (en) | 2005-10-11 | 2007-05-24 | Centre National De La Recherche Scientifique (Cnrs) | 3 -hydroxyflavone derivatives for the detection and the quantification of cell apoptosis |
| NZ546477A (en) | 2006-04-07 | 2009-04-30 | Auckland Uniservices Ltd | 4-Alkylamino-2-(heterocyclic)quinazolines and their use in cancer therapy |
| WO2008153701A1 (en) | 2007-05-24 | 2008-12-18 | Schering Corporation | Compounds for inhibiting ksp kinesin activity |
| CA2696113A1 (en) | 2007-08-10 | 2009-04-02 | Burnham Institute For Medical Research | Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof |
| WO2010127208A1 (en) | 2009-04-30 | 2010-11-04 | Forest Laboratories Holdings Limited | Inhibitors of acetyl-coa carboxylase |
| WO2012087938A1 (en) * | 2010-12-20 | 2012-06-28 | Glaxosmithkline Llc | Quinazolinone derivatives as antiviral agents |
| CN102838600A (zh) | 2011-06-24 | 2012-12-26 | 山东亨利医药科技有限责任公司 | 苯基喹唑啉类PI3Kδ抑制剂 |
| WO2014087165A1 (en) | 2012-12-06 | 2014-06-12 | University Of Bath | Tankyrase inhibitors |
| RU2718876C2 (ru) | 2013-08-23 | 2020-04-15 | Ньюфарма, Инк. | Некоторые химические соединения, композиции и способы |
| CN109134434B (zh) | 2017-11-06 | 2021-02-19 | 北京大学深圳研究生院 | 喹啉或喹唑啉类化合物及其制备方法和应用 |
| US10487057B1 (en) * | 2018-07-05 | 2019-11-26 | Landos Biopharma, Inc. | NLRX1 ligands |
-
2021
- 2021-09-20 IL IL301346A patent/IL301346A/en unknown
- 2021-09-20 US US17/479,337 patent/US11548885B2/en active Active
- 2021-09-20 WO PCT/US2021/051068 patent/WO2022061224A1/en active Application Filing
- 2021-09-20 CN CN202180064577.7A patent/CN116368133A/zh active Pending
- 2021-09-20 KR KR1020237012417A patent/KR20230074174A/ko active Search and Examination
- 2021-09-20 EP EP21790019.0A patent/EP4196475A1/en active Pending
- 2021-09-20 AU AU2021342568A patent/AU2021342568A1/en active Pending
- 2021-09-20 JP JP2023518124A patent/JP2023542921A/ja active Pending
- 2021-09-20 BR BR112023005189A patent/BR112023005189A2/pt unknown
- 2021-09-20 MX MX2023003273A patent/MX2023003273A/es unknown
- 2021-09-20 CA CA3192644A patent/CA3192644A1/en active Pending
- 2021-09-21 AR ARP210102616A patent/AR123560A1/es unknown
-
2022
- 2022-12-20 US US18/085,293 patent/US20230128450A1/en active Pending
-
2023
- 2023-03-20 CL CL2023000803A patent/CL2023000803A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL301346A (en) | 2023-05-01 |
| CL2023000803A1 (es) | 2023-11-17 |
| CN116368133A (zh) | 2023-06-30 |
| EP4196475A1 (en) | 2023-06-21 |
| US11548885B2 (en) | 2023-01-10 |
| BR112023005189A2 (pt) | 2023-04-25 |
| JP2023542921A (ja) | 2023-10-12 |
| AR123560A1 (es) | 2022-12-14 |
| US20230128450A1 (en) | 2023-04-27 |
| CA3192644A1 (en) | 2022-03-24 |
| KR20230074174A (ko) | 2023-05-26 |
| AU2021342568A9 (en) | 2024-10-10 |
| WO2022061224A1 (en) | 2022-03-24 |
| AU2021342568A1 (en) | 2023-04-20 |
| US20220089586A1 (en) | 2022-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502258A1 (en) | Isoquinolin-3-yl carboxamides and preparation and use thereof | |
| WO2018060732A3 (en) | Compositions and methods for treating seizure disorders | |
| WO2020160193A3 (en) | Compounds and uses thereof | |
| WO2017189823A3 (en) | Isoquinolin-3-yl carboxamides and preparation and use thereof | |
| EA201991375A1 (ru) | Бицикло[1.1.1]пентановые ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
| MX2018012655A (es) | Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares. | |
| WO2016100157A3 (en) | 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists | |
| MX2023009652A (es) | Inhibidores peptidicos de la acumulacion de alfa-sinucleina basados en estructuras. | |
| EP4275748A3 (en) | Compositions and methods for treating cns disorders | |
| MX2021004492A (es) | Composiciones para el tratamiento de trastornos del snc. | |
| PH12016501600A1 (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| MX2021004582A (es) | Compuesto 2-azabiciclo hexano inhibidor de jak. | |
| WO2016100162A3 (en) | 5,5-bicyclic oxazole orexin receptor antagonists | |
| AU2012277802A8 (en) | Novel inhibitor compounds of phosphodiesterase type 10A | |
| WO2015108490A3 (en) | Heteroaryl alkyne derivatives and uses thereof | |
| EP4356969A3 (en) | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections | |
| MX2021002521A (es) | Dimetilaminoazetidinaminas como inhibidores de jak. | |
| EA201990450A1 (ru) | Ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
| WO2018023072A3 (en) | Compounds and compositions and uses thereof | |
| TN2018000372A1 (en) | Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions. | |
| PH12020552092A1 (en) | Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease | |
| MX2019006495A (es) | Tratamiento de enfermedades neurologicas. | |
| MX2019004859A (es) | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. | |
| BR112017008103A2 (pt) | composto, composição farmacêutica, métodos para tratar uma doença e uma condição, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo e de um segundo agente ativo. | |
| SA519401322B1 (ar) | مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2 |